Translational Scientist - Drug Development: Cancer Research UK

Please note that we will be shortlisting for interview on a rolling basis so early application is strongly encouraged to avoid any disappointment.


Are you a Translational scientist with broad experience across preclinical and early clinical development? Could you help us plan and implement pharmacology and toxicology packages to support submissions for vaccines, cell therapies or biologicals?


Why we need you

Cancer Research UK’s Centre for Drug Development (CDD) is a centre of excellence in early phase cancer drug development. We provide the expertise, facilities and close connections with industry and academia to translate today’s science into tomorrow’s medicine. We have a pioneering portfolio with a focus on developing First-in-Class therapeutic and diagnostic agents. We currently have over 20 projects in active development including antibodies, imaging agents, cell therapies and vaccines and small molecules.


The CDD Translational Sciences team is an established and experienced group of clinicians, biomarker scientists and translational scientists. We are looking for a scientist with a strong immunology or cell therapy background, and with solid experience of delivering toxicology and pharmacology packages to support First-in-Human studies. The successful candidate will independently represent the translational group on a number of multidisciplinary project teams delivering our portfolio of projects.


What will I be doing?

Make an impact every day by:

  • Applying your knowledge to define and support preclinical and translational activities for novel therapeutics from portfolio entry through Phase 1 and 2 trials.
  • Designing, delivering and documenting preclinical studies and/or scientific justifications adequate to support acceptance of clinical trial authorisation applications.
  • Working closely with project teams, clinical investigators and scientific experts to inform the design of First-in-Human clinical trials.
  • Supporting the interpretation of emerging data from clinical trials.


What skills are we looking for?

You’ll be able to bring to the role:

  • Track record in leading translational strategies and activities for development of small molecules, antibodies, vaccines or cell therapies.
  • Scientific background in cell therapy, vaccines or immune modulators. Experience in oncology projects beneficial.
  • Experience of planning, executing and interpreting pharmacology and/or toxicology studies, including working with contract research organisations.
  • Experience of authoring regulatory documents to support First-in-Human studies.
  • Ability to apply yourself to multiple projects spanning a range of therapeutic modalities.

To view a full job description please click here:


What will I gain?

The role offers the opportunity to work closely with world class investigators and partners, and to gain broad exposure across the wide range of novel therapeutics in our pipeline.


Without you we wouldn’t be able to achieve our aim of seeing 3 in 4 people survive cancer by 2034. We want to reward you in as many ways as possible. Our benefits package includes discounts on anything from travel to technology, generous holiday allowance, pension, gym membership, childcare vouchers and much more. You’ll also be able to access a wide range of learning and development opportunities. Ultimately you’ll know that you’ll be changing lives through your work. 


If you’re as ambitious as we are, join our collective force and enjoy an excellent career, as we save lives and add years.


Please submit your CV and cover letter through our careers pages.


At CRUK we value diversity and we're committed to creating an inclusive culture where everyone is able to be themselves and to reach their full potential. We actively encourage applications from people of all backgrounds and cultures and believe that a diverse workforce will help us to beat cancer sooner. Should you need any adjustments to the recruitment process, at either application or interview, please contact us on

Closing date: 
Monday, January 20, 2020
Originating organisation: